Cell Kinetics Ltd. (CKNTF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cell Kinetics Ltd. (CKNTF) trades at $0.0001 with AI Score 46/100 (Grade C). Cell Kinetics Ltd. focuses on refining and commercializing CellScan technology. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for CKNTF: CKNTF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CKNTF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CKNTF: 1/2 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Cell Kinetics Ltd. (CKNTF) Healthcare & Pipeline Overview
Cell Kinetics Ltd., a subsidiary of Medis Technologies, specializes in cell carrier technology, specifically the CKChip platform, enabling simultaneous examination of live cells through imaging. Operating in the medical devices sector, the company focuses on refining and commercializing CellScan technology for advanced cell analysis applications.
What Is the Investment Thesis for CKNTF?
Cell Kinetics Ltd. presents a focused investment opportunity within the medical devices sector, centered on its CKChip platform for cell analysis. The company's technology enables detailed examination of live cells, potentially driving adoption in research and diagnostic applications. A key value driver is the continued refinement and commercialization of CellScan technology, targeting a market need for efficient cell analysis tools. Growth catalysts include expanding the applications of CKChip technology and securing partnerships within the healthcare and research sectors. However, potential risks include the company's OTC listing, limited financial information, and competition from established players in the cytometry market. With a market capitalization of $0.00B and a beta of -10.63, the company's financial profile requires careful consideration.
Based on FMP financials and quantitative analysis
CKNTF Key Highlights
Cell Kinetics Ltd. specializes in cell carrier technology known as CKChip.
- The CKChip platform enables simultaneous examination of various individual live cells.
- The company's technology uses simple imaging methods such as fluorescence microscopy.
- Cell Kinetics Ltd. was founded in 1992 and is headquartered in Lod, Israel.
- The company is a subsidiary of Medis Technologies Ltd.
Who Are CKNTF's Competitors?
CKNTF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $3.01 | +4.88% | $19.6M | 60 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -1.08% | $24.6M | 73 |
| RDGL Vivos Inc. | $0.05 | -5.33% | $26.5M | 61 |
| NVYTF Novacyt S.A. | $0.48 | -0.00% | $34.8M | 61 |
| DNAY Codex DNA, Inc. | $1.30 | +8.33% | $38.3M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CKNTF's Key Strengths?
Proprietary CKChip technology for cell analysis.
- Focus on static cytometry.
- Potential for cost-effective live cell examination.
What Are CKNTF's Weaknesses?
OTC listing and limited financial information.
- Small company size and limited resources.
- Dependence on Medis Technologies Ltd.
What Could Drive CKNTF Stock Higher?
Potential partnerships with diagnostic companies to integrate CKChip technology into diagnostic assays.
- Continued refinement and commercialization of CellScan technology.
- Efforts to expand the applications of CKChip technology.
What Are the Key Risks for CKNTF?
Competition from established players in the cytometry market.
- Regulatory hurdles for new diagnostic applications.
- OTC listing and limited financial information.
- Small company size and limited resources.
What Are the Growth Opportunities for CKNTF?
- Expansion into Research Institutions: Cell Kinetics can target research institutions and universities to adopt the CKChip platform for advanced cell analysis. The market for research tools in cell biology is substantial, with institutions continuously seeking innovative technologies. By demonstrating the efficiency and cost-effectiveness of CKChip, Cell Kinetics can penetrate this market, potentially securing long-term contracts and collaborations. This expansion could be realized within the next 1-2 years, driving revenue growth and establishing the company as a key player in research applications.
- Partnerships with Diagnostic Companies: Collaborating with diagnostic companies to integrate CKChip technology into diagnostic assays represents a significant growth opportunity. The demand for accurate and rapid diagnostic tools is increasing, and CKChip's ability to analyze live cells can enhance the precision of diagnostic tests. Forming strategic partnerships with companies specializing in cancer diagnostics or infectious disease testing can accelerate market penetration and generate revenue through licensing agreements and joint product development. These partnerships could materialize within the next 2-3 years, contingent on successful validation studies and regulatory approvals.
- Development of New Applications for CKChip: Cell Kinetics can invest in research and development to explore new applications for the CKChip platform beyond its current capabilities. This includes adapting the technology for use in drug discovery, personalized medicine, and regenerative medicine. By expanding the range of applications, Cell Kinetics can attract a broader customer base and diversify its revenue streams. The development of new applications may take 3-5 years, requiring sustained investment in R&D and collaboration with experts in relevant fields.
- Geographic Expansion into New Markets: Cell Kinetics can expand its geographic presence by targeting new markets in Europe and Asia. These regions have a growing demand for advanced cell analysis technologies, driven by increasing healthcare spending and research activities. Establishing distribution networks and partnerships in these markets can facilitate market entry and generate revenue growth. Geographic expansion can be pursued within the next 2-3 years, contingent on securing regulatory approvals and establishing local partnerships.
- Securing Government Grants and Funding: Cell Kinetics can actively pursue government grants and funding opportunities to support its research and development activities. Government agencies and research foundations often provide funding for innovative technologies in healthcare and biotechnology. Securing these grants can provide Cell Kinetics with additional resources to accelerate the development and commercialization of its CKChip platform. The timeline for securing grants varies depending on the specific funding programs, but ongoing efforts to identify and apply for relevant grants can yield positive results within the next 1-2 years.
What Are CKNTF's Competitive Advantages?
- Proprietary CKChip technology.
- Specialized focus on static cytometry.
- Potential for cost-effective cell analysis.
What Does CKNTF Do?
Founded in 1992 and headquartered in Lod, Israel, Cell Kinetics Ltd. is dedicated to the advancement of cell analysis technologies. The company's core focus is the refinement and commercialization of CellScan and related technologies, with a particular emphasis on the CKChip platform. This platform employs static cytometry, allowing for the simultaneous examination of various individual live cells through simple imaging methods, such as fluorescence microscopy. The CKChip technology facilitates detailed cellular analysis, potentially impacting research and diagnostic applications. As a subsidiary of Medis Technologies Ltd., Cell Kinetics benefits from the resources and infrastructure of its parent company. The company's operations are centered around developing and marketing this cell carrier technology, aiming to provide researchers and clinicians with tools for advanced cell analysis. Cell Kinetics' technology is designed to offer a cost-effective and efficient method for examining live cells, potentially improving the speed and accuracy of cellular research and diagnostics. The company's strategic focus on static cytometry positions it within a niche market of cell analysis, where it aims to provide innovative solutions for live cell examination.
What Products and Services Does CKNTF Offer?
- Refines and commercializes CellScan technology.
- Develops and commercializes CKChip, a cell carrier technology.
- Offers a platform for static cytometry.
- Enables simultaneous examination of various individual live cells.
- Uses simple imaging methods, such as fluorescence microscopy.
- Provides tools for advanced cell analysis.
How Does CKNTF Make Money?
- Develops and sells cell carrier technology (CKChip).
- Commercializes CellScan technology.
- Generates revenue through sales of its technology to research institutions and diagnostic companies.
What Industry Does CKNTF Operate In?
Cell Kinetics Ltd. operates within the medical devices industry, specifically focusing on cell analysis technologies. The market for cell analysis is driven by advancements in research and diagnostics, with increasing demand for tools that enable detailed cellular examination. The competitive landscape includes companies offering cytometry solutions, such as Maravai LifeSciences Holdings, Inc. (MRVT), and genetic testing services like Invitae Corporation (NVTAQ). Cell Kinetics' CKChip platform aims to provide a cost-effective and efficient method for live cell examination, positioning it within a niche segment of the broader cell analysis market.
Who Are CKNTF's Key Customers?
- Research institutions
- Diagnostic companies
- Healthcare providers
Company Profile
Cell Kinetics Ltd. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Lod, IL. The company is led by CEO Stephen N. Crea. CKNTF has traded publicly since 2008.
CKNTF Valuation & Market Position
Relative to its peer group, CKNTF's quantitative score of 46/100 is below the peer average of 65/100.
Key Financial Metrics
Return on equity for Cell Kinetics Ltd. stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. CKNTF trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
CKNTF Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying signals confidence from those closest to the company, suggesting they believe the stock is undervalued or poised for growth.
- Community sentiment appears to be shifting positively, with more users expressing optimism about the company's long-term prospects and potential breakthroughs.
- The company's focus on cell kinetics is gaining traction as a promising area in medical research, potentially attracting more institutional interest. Think CRISPR's early days.
- Despite market volatility, the company seems to be maintaining a steady course, fostering trust among investors looking for stability in a turbulent sector.
Bear Case
- Limited news flow in the last month raises concerns about the company's visibility and ability to attract new investors.
- Bearish community members point to the slow pace of regulatory approvals as a significant hurdle to commercialization.
- The company operates in a highly competitive landscape, facing established players with greater resources and market share. It's a David vs. Goliath situation.
- Skeptics highlight the potential for clinical trial setbacks, which could significantly impact the company's valuation and future prospects.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CKNTF Latest News
No recent news available for CKNTF.
CKNTF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CKNTF.
Price Targets
Wall Street price target analysis for CKNTF.
CKNTF MoonshotScore
What does this score mean?
The MoonshotScore rates CKNTF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Stephen N. Crea
CEO
Stephen N. Crea serves as the CEO of Cell Kinetics Ltd., managing a team of 10 employees. His background includes experience in the healthcare and biotechnology sectors. While specific details on his educational background and previous roles are not available, his leadership is focused on guiding Cell Kinetics in the refinement and commercialization of its CellScan and CKChip technologies.
Track Record: Under Stephen N. Crea's leadership, Cell Kinetics Ltd. continues to focus on the development and commercialization of its cell carrier technology. Key milestones include ongoing efforts to expand the applications of CKChip and secure partnerships within the healthcare and research sectors. His strategic decisions are centered on driving adoption of the company's technology and enhancing its market presence.
CKNTF OTC Market Information
The OTC Other tier represents the lowest tier of over-the-counter (OTC) markets, indicating that Cell Kinetics Ltd. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited or no financial reporting, making it difficult for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, resulting in higher risks for investors due to the lack of transparency and oversight.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low trading volume and illiquidity.
- Potential for price manipulation and fraud.
- Lack of regulatory oversight and investor protection.
- Higher risk of delisting or going out of business.
- Verify the company's legal status and registration.
- Attempt to obtain and review any available financial statements.
- Assess the company's management team and their experience.
- Understand the company's business model and competitive landscape.
- Evaluate the company's technology and intellectual property.
- Consult with a financial advisor or legal expert.
- Be prepared to lose your entire investment.
- Company has been in operation since 1992.
- Focus on refining and commercializing CellScan technology.
- Subsidiary of Medis Technologies Ltd.
CKNTF Healthcare Stock FAQ
What does the AI Score mean for CKNTF?
CKNTF holds an AI Score of 46/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Cell Kinetics Ltd. focuses on refining and commercializing CellScan technology. The company develops CKChip, a platform static cytometry technology for examining individual live cells using …
What does Cell Kinetics Ltd. do?
Cell Kinetics Ltd. specializes in the development and commercialization of cell analysis technologies, primarily focusing on its CKChip platform. This platform utilizes static cytometry to enable the simultaneous examination of individual live cells through imaging methods like fluorescence microscopy.
What are the key growth opportunities for CKNTF in healthcare?
Cell Kinetics Ltd. has several growth opportunities within the healthcare sector. These include expanding into research institutions by offering the CKChip platform for advanced cell analysis, forming partnerships with diagnostic companies to integrate CKChip technology into diagnostic assays, developing new applications for CKChip in areas like drug discovery and personalized medicine, and expanding geographically into new markets in Europe and Asia.
How does Cell Kinetics Ltd. navigate regulatory approval processes?
As a company developing cell analysis technologies, Cell Kinetics Ltd. faces regulatory approval processes, particularly if its technology is integrated into diagnostic applications. The company needs to comply with regulations set by agencies like the FDA in the United States and the EMA in Europe.
What are the key factors to evaluate for CKNTF?
Cell Kinetics Ltd. (CKNTF) holds an AI score of 46/100 (low). presents a focused investment opportunity within the medical devices sector, centered on its CKChip platform for cell analysis. Not financial advice.
How frequently does CKNTF data refresh on this page?
CKNTF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CKNTF's recent stock price performance?
Cell Kinetics Ltd. (CKNTF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary CKChip technology for cell analysis. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CKNTF overvalued or undervalued right now?
Cell Kinetics Ltd. (CKNTF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CKNTF before investing?
Before investing in Cell Kinetics Ltd. (CKNTF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial information available due to OTC listing.
- AI analysis pending for CKNTF.